Clinical efficacy and safety of Cadonilimab immunotherapy in recurrent or metastatic gynecological malignancies: a retrospective study

Key Points

• Cadonilimab immunotherapy shows clinical efficacy against recurrent gynecological malignancies, enhancing survival rates.
• Patients treated with cadonilimab demonstrated a 50% response rate over the study period.
• Retrospective analysis evaluated clinical outcomes from multiple centers across diverse patient demographics.
• These findings indicate the need for further investigation into cadonilimab's long-term safety and efficacy.